Rights and permissions
About this article
Cite this article
Adolescent meningococcal vax feasible, but societal cost high. Pharmacoecon. Outcomes News 483, 9 (2005). https://doi.org/10.2165/00151234-200504830-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504830-00020